Funded Research: Advance HIV Prevention Tech
Posted: November 28, 2008
This grant closed on Mar 13, 2009. We have found similar active grants for you below.
Summary
Biotech and pharma companies can secure significant funding to develop innovative topical microbicides and combination strategies for HIV prevention. This program supports integrated research projects aimed at creating safer solutions for the sexual transmission of HIV.
Eligibility
Full Description
Purpose. The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH) invite applications from single institutions and consortia of institutions to participate in this Funding Opportunity Announcement (FOA), Integrated Preclinical/Clinical Program for HIV Topical Microbicides (IPCP-HTM).The purpose of this FOA is to support integrated and iterative multi-project, multi-disciplinary preclinical and exploratory clinical studies with the goal of advancing safe, novel topical microbicides and microbicide combination strategies for the prevention of sexual transmission of HIV. A minimum of two research projects and an Administrative Core must be proposed. At least one component (research project or scientific core) must be a private sector profit or not-for-profit small, domestic or foreign, pharmaceutical, chemical, bioengineering or biotechnological company.A Scientific Advisory Panel (SAP) for each award under this FOA will be constituted post award but no later than 12 months after award.
Mechanism of Support. This FOA will utilize the multi-project Cooperative Agreement (U19) grant mechanism. Funds Available and Anticipated Number of Awards. NIAID and NIMH anticipate awarding a total of $5.0 million in FY 2010.NIMH and NIAID will contribute $0.5 million and $4.5 million to the IPCP-HTM respectively.
Two to three new awards are anticipated in response to this RFA.